APT Pharmaceuticals is a drug
development company focused on repurposing well-characterized
drugs for under-served populations.
APT’s initial focus
is on the pulmonary delivery of treatments for serious lung
diseases. The company also has active programs in cardioprotection
and allergic airways disease.
The company’s lead program,
Pulminiq™ (cyclosporine, USP Inhalation solution), will
enter Phase III for the prevention of chronic lung transplant
rejection in early 2008. |
